Incurred Sample Reanalysis (ISR): A Decisive Tool in Bioanalytical Research

10.1023/A:1015829422034

10.1208/aapsj0901005

10.1023/A:1007669411738

US FDA . Guidance for industry bioanalytical method validation. US Department of Health and Human Services, FDA Center for Drug Evaluation and Research, MD, USA (2001).

10.1007/BF02493126

10.1208/aapsj0901004

10.1208/aapsj0903040

10.1208/aapsj0901011

10.1208/aapsj0902013

10.1208/aapsj0902014

10.1208/aapsj0902017

10.1208/s12248-009-9100-9

10.1016/j.jchromb.2009.08.019

10.1016/j.jchromb.2009.09.017

10.1016/j.jchromb.2010.09.022

10.4155/bio.09.108

10.1016/S0003-2670(03)00407-0

10.1016/j.jpba.2007.09.006

10.4155/bio.10.164

10.4155/bio.10.34

10.4155/bio.10.39

Bryan PD . What is incurred sample analysis and why is it important? AAPS Newsmagazine11(9), 18–22 (2008).

10.1023/A:1018922701174

10.4155/bio.09.79

10.1016/S0140-6736(95)91748-9

10.1177/096228029900800204

10.1177/1087057105285611

10.1093/clinchem/43.11.2039

10.1016/j.jchromb.2010.06.028

10.1093/chromsci/48.10.811

10.1093/chromsci/48.9.704

10.1093/chromsci/48.8.654

10.1365/s10337-010-1667-x

10.1016/j.jchromb.2009.01.042

Guidance for Industry: ICH E6 Good Clinical Practice U.S. Department of Health and Human Services Food and Drug Administration Centre for Drug Evaluation and Research (CDER) Centre for Biologics Evaluation and Research (CBER) (1996).

10.1016/j.jchromb.2008.07.026

10.1016/j.chroma.2006.01.058

10.1016/j.jpba.2009.10.023

10.1093/chromsci/46.10.867

10.1016/j.jchromb.2010.03.044

10.1016/j.forsciint.2008.03.018

10.1016/S0149-2918(01)80027-8

10.1039/c0ay00062k

10.1016/j.jchromb.2005.07.027

Website Health Canada. Conduct and analysis of bioavailability and bioequivalence studies-Part A: oral dosage formulations used for systemic effects. www.hc-sc.gc.ca/dhp-mps/proinsituharma/applic-demande/guide-Id/bio/bio-b-eng.php (Accessed December2010)

APPS Third Bioanalytical Workshop: Quantitative Bioanalytical Methods Validation and Implementation. Crystal City VA USA (2006). www.aapspharmaceutica.com (Accessed December2010)

AAPS Workshop on Topics in GLP Bioanalysis: Assay Reproducibility for Incurred Samples. Crystal City VA USA (2008). www.aapspharmaceutica.com (Accessed December2010)

Bansal SB. AAPS Bioanalytical Survey. The APPS Third Bioanalytical Workshop: Quantitative Bioanalytical Methods Validation and Implementation. Crystal City VA USA (2006). www.aapspharmaceutica.com (Accessed December2010)

Weiner R. Incurred sample survey results. The AAPS Workshop on Topics in GLP Bioanalysis: Assay Reproducibility for Incurred Samples. Crystal City VA USA (2008). www.aapspharmaceutica.com (Accessed December2010)

Bansal SB. Did incurred sample reanalysis raise confidence in bioanalytical results? The AAPS Workshop on Topics in GLP Bioanalysis: Assay Reproducibility for Incurred Samples. Crystal City VA USA (2008). www.aapspharmaceutica.com (Accessed December2010)

Viswanathan CT. The year in bioanalytical regulatory findings. The Applied Pharmaceutical Analysis Conference. Harvard Medical School Boston MA USA (2008). www.applieinsituharmaceuticalanalysis.org (Accessed December2010)

Website Health Canada. Conduct and analysis of bioavailability and bioequivalence studies – Part B: oral modified-release formulations. www.hc-sc.gc.ca/dhp-mps/proinsituharma/applic-demande/guide-Id/bio/bio-b-eng.php (Accessed December2010)

Website Health Canada. Notice to industry – removal of requirement for 15% random replicate sample notice affecting guideline A and guideline B requirements. www.hc-sc.gc.ca/dhp-mps/proinsituharma/applic-demande/guide-Id/bio/15rep-eng.php (Accessed December2010)

Garafolo F. The Canadian workshop on the Crystal City AAPS/FDA White Paper. www.canadianlcmsgroup.com/docs/b (Accessed December2010)

Bansal SB. Repeat bioanalysis selection and reporting. APPS Workshop: quantitative bioanalytical methods validation and implementation: best practices for chromatographic and liqand binding assays (2006). www.aapspharmaceutica.com (Accessed December2010)

European Medicines Agency Committee for Medicinal Products for Human Use Guidelines on Validation of Bioanalytical Methods (draft) EMA/CMP/EWP/192217/ 2009. www.ema.europa.eu/ema (Accessed December2010)